Utah Medical Products (UTMD) AI Stock Analysis

• Market Cap: $182.03M
• Dividend Yield: 2.15%
• Average Volume (3M): 12.83K
• Price to Earnings (P/E): 14.8
• Beta (1Y): 0.48
• Revenue Growth: -19.92%
• EPS Growth: N/A
• Country: US
• Employees: 155
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 3.78
• Shares Outstanding: 3,248,210
• 10 Day Avg. Volume: 10,484
• 30 Day Avg. Volume: 12,833
• PEG Ratio: -1.82
• Price to Book (P/B): 1.62
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 12.43
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 67 Neutral
• Price Target: ―

Utah Medical Products receives a score of 67.25 driven by strong financial health characterized by high profitability and a solid balance sheet, although challenged by recent declines in revenue and operating cash flow. The technical indicators are currently negative, suggesting short-term volatility, but the stock's valuation appears attractive with a low P/E ratio and decent dividend yield.

Utah Medical Products Business Overview & Revenue Model

Company Description

Utah Medical Products, Inc. (UTMD) is a company that specializes in the development, manufacture, and distribution of medical devices used in healthcare facilities. The company primarily focuses on products that serve the needs of healthcare practitioners and patients in the areas of neonatal care, labor and delivery, gynecology, and critical care. UTMD's product offerings include a range of specialty devices such as blood pressure monitoring equipment, neonatal intensive care products, and systems used in obstetrics and gynecology procedures.

How the Company Makes Money

Utah Medical Products makes money through the production and sale of its medical devices to healthcare providers, hospitals, and clinics. The company generates revenue by selling its products directly to medical facilities and through distributors in both domestic and international markets. Furthermore, UTMD benefits from long-term relationships and contracts with healthcare institutions, which ensure a steady demand for its products. The company's revenue streams are primarily derived from the sale of proprietary medical devices, which are often protected by patents, enabling UTMD to maintain competitive pricing and margins. Additionally, UTMD's focus on niche markets with specialized products allows it to capitalize on less competitive segments of the medical device industry.

Utah Medical Products Financial Statement Overview

Summary

Utah Medical Products presents a strong financial profile with excellent profitability and a robust balance sheet. The company has maintained healthy margins and low leverage, indicating stability and potential growth. However, the recent decline in revenue and operating cash flow could pose challenges if not addressed.

Income Statement

Utah Medical Products has demonstrated strong profitability with a consistent gross profit margin averaging around 60% and net profit margins exceeding 30% in recent years. However, the company experienced a decline in revenue growth in the latest year, showing a decrease in total revenue from $52.28 million in 2022 to $50.22 million in 2023. Despite this, the EBIT and EBITDA margins have remained robust, indicating efficient operations.

Balance Sheet

The company exhibits a strong balance sheet with a low debt-to-equity ratio close to 0, reflecting minimal leverage. The return on equity has been impressive, supported by solid net income figures. The equity ratio is high, indicating a stable financial structure with a significant portion of assets financed by equity, minimizing financial risk.

Cash Flow

Cash flow analysis shows mixed results. While the company has consistently generated positive free cash flow, there was a notable decline in operating cash flow from $22.28 million in 2023 to $0 in 2024. This abrupt change suggests potential operational challenges or shifts in cash management strategies. Despite this, the historical consistency in free cash flow generation indicates underlying financial health.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
40.90M	50.22M	52.28M	49.05M	42.18M
	Gross Profit
24.14M	30.04M	32.20M	30.92M	25.55M
	EBIT
13.59M	16.78M	12.71M	18.88M	6.50M
	EBITDA
16.44M	24.75M	26.87M	26.16M	20.92M
	Net Income Common Stockholders
13.87M	16.64M	16.47M	14.79M	10.80M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
82.98M	92.87M	75.05M	60.97M	51.59M
	Total Assets
122.54M	135.46M	123.87M	115.56M	111.75M
	Total Debt
282.00K	295.00K	341.00K	331.00K	335.00K
	Net Debt
-82.69M	-92.57M	-74.71M	-60.64M	-51.26M
	Total Liabilities
5.11M	7.14M	9.62M	8.42M	8.92M
	Stockholders Equity
117.43M	128.31M	114.25M	107.14M	102.82M
Cash Flow		Free Cash Flow
0.00	21.64M	20.33M	20.65M	19.28M
	Operating Cash Flow
0.00	22.28M	21.15M	21.20M	20.14M
	Investing Cash Flow
0.00	-639.00K	-818.00K	-552.00K	-860.00K
	Financing Cash Flow
0.00	-4.17M	-5.48M	-10.90M	-10.73M

Utah Medical Products Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 56.16
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UTMD, the sentiment is Neutral. The current price of 56.16 is above the 20-day moving average (MA) of 54.67, above the 50-day MA of 54.06, and below the 200-day MA of 60.66, indicating a neutral trend. The MACD of 0.51 indicates Negative momentum. The RSI at 62.95 is Neutral, neither overbought nor oversold. The STOCH value of 87.96 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for UTMD.

Utah Medical Products Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INFU	71 Outperform	$124.38M	41.62	5.94%	―	7.98%	3304.55%
UTMD	67 Neutral	$182.03M	14.84	10.59%	2.15%	-19.92%	―
STXS	64 Neutral	$193.50M	―	-179.82%	―	1.50%	-20.00%
PDEX	63 Neutral	$137.71M	15.33	28.29%	―	29.65%	131.78%
OSUR	57 Neutral	$216.17M	25.27	-7.77%	―	-46.95%	-237.44%
Sector *	54 Neutral	$5.31B	3.29	-45.39%	2.79%	16.77%	-0.07%
SMTI	50 Neutral	$262.10M	―	-28.58%	―	34.65%	-128.56%